Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382279263> ?p ?o ?g. }
- W4382279263 endingPage "1827" @default.
- W4382279263 startingPage "1827" @default.
- W4382279263 abstract "Platinum-based chemotherapy combined with anti-PD-1 or PD-L1 monoclonal antibodies (mAbs) is now standard first-line therapy for mNSCLC patients without sensitizing driver mutations. Anti-PD-1 and anti-PD-L1 mAbs are considered to be equivalent in efficacy. In the absence of head-to-head randomized control trials (RCTs), we utilized network meta-analysis (NWM) to provide an indirect comparison of their efficacy. A systematic literature review and NWM were performed using RCTs that investigated anti-PD-1 or PD-L1 mAbs ± chemotherapy in patients with mNSCLC in the first-line setting. The primary outcome was comparative overall survival (OS), while secondary outcomes were comparative progression-free survival (PFS), objective response rate (ORR), and rate of grade 3 and higher toxicities. We identified 24 RCTs. Patients treated with anti-PD-1 mAb + chemotherapy compared with anti-PD-L1 mAb + chemotherapy showed superior mOS, mPFS, and ORR with a similar rate of grade 3 and higher toxicities. This difference in mOS was most pronounced in the PD-L1 TPS 1–49% population. The two mAbs were equivalent as single agents. Anti-PD-1 mAb + chemotherapy improved mOS when compared to anti-PD-1 mAb monotherapy, whereas anti-PD-L1 mAbs + chemotherapy did not when compared to anti-PD-L1 mAb monotherapy. Head-to-head RCTs are warranted in the future." @default.
- W4382279263 created "2023-06-28" @default.
- W4382279263 creator A5000949291 @default.
- W4382279263 creator A5031601262 @default.
- W4382279263 creator A5037936050 @default.
- W4382279263 creator A5042115782 @default.
- W4382279263 creator A5048913973 @default.
- W4382279263 creator A5062164374 @default.
- W4382279263 creator A5063111253 @default.
- W4382279263 creator A5085372050 @default.
- W4382279263 date "2023-06-26" @default.
- W4382279263 modified "2023-10-17" @default.
- W4382279263 title "Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis" @default.
- W4382279263 cites W1957029226 @default.
- W4382279263 cites W1978952945 @default.
- W4382279263 cites W2028915915 @default.
- W4382279263 cites W2038218697 @default.
- W4382279263 cites W2098923148 @default.
- W4382279263 cites W2125435699 @default.
- W4382279263 cites W2135079975 @default.
- W4382279263 cites W2155464214 @default.
- W4382279263 cites W2323143415 @default.
- W4382279263 cites W2588681363 @default.
- W4382279263 cites W2635951006 @default.
- W4382279263 cites W2753065806 @default.
- W4382279263 cites W2753432434 @default.
- W4382279263 cites W2781525129 @default.
- W4382279263 cites W2792937256 @default.
- W4382279263 cites W2802662046 @default.
- W4382279263 cites W2892009523 @default.
- W4382279263 cites W2900347882 @default.
- W4382279263 cites W2910245285 @default.
- W4382279263 cites W2925446385 @default.
- W4382279263 cites W2935577863 @default.
- W4382279263 cites W2946386783 @default.
- W4382279263 cites W2947220371 @default.
- W4382279263 cites W2956407134 @default.
- W4382279263 cites W2981701180 @default.
- W4382279263 cites W2986633517 @default.
- W4382279263 cites W3009099064 @default.
- W4382279263 cites W3016210953 @default.
- W4382279263 cites W3017322331 @default.
- W4382279263 cites W3021099711 @default.
- W4382279263 cites W3025022288 @default.
- W4382279263 cites W3031396542 @default.
- W4382279263 cites W3034612062 @default.
- W4382279263 cites W3037506839 @default.
- W4382279263 cites W3043703771 @default.
- W4382279263 cites W3088724894 @default.
- W4382279263 cites W3091399767 @default.
- W4382279263 cites W3092159910 @default.
- W4382279263 cites W3093317346 @default.
- W4382279263 cites W3093708469 @default.
- W4382279263 cites W3097223462 @default.
- W4382279263 cites W3110814768 @default.
- W4382279263 cites W3111665711 @default.
- W4382279263 cites W3128646645 @default.
- W4382279263 cites W3129022890 @default.
- W4382279263 cites W3130042079 @default.
- W4382279263 cites W3152729586 @default.
- W4382279263 cites W3164336527 @default.
- W4382279263 cites W3164993995 @default.
- W4382279263 cites W3165007730 @default.
- W4382279263 cites W3167668640 @default.
- W4382279263 cites W3183409909 @default.
- W4382279263 cites W3211469814 @default.
- W4382279263 cites W4200204256 @default.
- W4382279263 cites W4205759188 @default.
- W4382279263 cites W4212811623 @default.
- W4382279263 cites W4224297766 @default.
- W4382279263 cites W4281658223 @default.
- W4382279263 cites W4281670120 @default.
- W4382279263 cites W4281696342 @default.
- W4382279263 cites W4285809093 @default.
- W4382279263 cites W4288459215 @default.
- W4382279263 cites W4289340248 @default.
- W4382279263 cites W4293083613 @default.
- W4382279263 cites W4293237625 @default.
- W4382279263 cites W4296767555 @default.
- W4382279263 cites W4308179948 @default.
- W4382279263 doi "https://doi.org/10.3390/biomedicines11071827" @default.
- W4382279263 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37509467" @default.
- W4382279263 hasPublicationYear "2023" @default.
- W4382279263 type Work @default.
- W4382279263 citedByCount "0" @default.
- W4382279263 crossrefType "journal-article" @default.
- W4382279263 hasAuthorship W4382279263A5000949291 @default.
- W4382279263 hasAuthorship W4382279263A5031601262 @default.
- W4382279263 hasAuthorship W4382279263A5037936050 @default.
- W4382279263 hasAuthorship W4382279263A5042115782 @default.
- W4382279263 hasAuthorship W4382279263A5048913973 @default.
- W4382279263 hasAuthorship W4382279263A5062164374 @default.
- W4382279263 hasAuthorship W4382279263A5063111253 @default.
- W4382279263 hasAuthorship W4382279263A5085372050 @default.
- W4382279263 hasBestOaLocation W43822792631 @default.
- W4382279263 hasConcept C121608353 @default.
- W4382279263 hasConcept C126322002 @default.
- W4382279263 hasConcept C143998085 @default.